Medicare Advantage insurers had urged CMS to scrap the obesity drug coverage proposals and eliminate a health equity payment ...

Prior authorizations create substantial administrative and financial burdens on physicians and patients and can disrupt the continuity of care.

The Food and Drug Administration (FDA) has expanded the approval of Pluvicto® (lutetium Lu 177 vipivotide tetraxetan) to include patients with ...